drugset

drugset / Trial / NCT07583849

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD

NCT07583849 ↗

Phase 3 Recruiting 376 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of a 12-week administration of HSK39004 inhalation powder in clinical trial participants with COPD

Timeline

Start: 2026-05-24
Primary completion: 2027-09-30
Completion: 2027-10-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK39004	Unknown	0.75 mg	Oral

Indications